

RESEARCH ARTICLE

Cancer Therapy and Prevention

The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E₂ synthesis and platelet activation in participants of the seAFOod polyp prevention trial

Ge Sun¹ | Harriett Fuller¹ | Hayley Fenton¹ | Amanda D. Race² | Amy Downing¹ | Elizabeth A. Williams³ | Colin J. Rees⁴ | Louise C. Brown⁵ | Paul M. Loadman² | Mark A. Hull¹  

¹Leeds Institute of Medical Research, University of Leeds, Leeds, UK

²Institute of Cancer Therapeutics, University of Bradford, Bradford, UK

³School of Medicine and Population Health, University of Sheffield, Sheffield, UK

⁴Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK

⁵MRC Clinical Trials Unit at University College, London, UK

Correspondence

Mark A. Hull, Division of Gastrointestinal and Surgical Sciences, Leeds Institute of Medical Research, St James's University Hospital, University of Leeds, Leeds, LS9 7TF, UK.
Email: m.a.hull@leeds.ac.uk

Funding information

Efficacy and Mechanism Evaluation Programme, Grant/Award Number: NIHR128210; Cancer Research UK, Grant/Award Number: C23434/A24939

Abstract

Urinary prostaglandin (PG) E metabolite (PGE-M) and 11-dehydro (d)-thromboxane (TX) B₂ are biomarkers of cyclooxygenase-dependent prostanoid synthesis. We investigated (1) the effect of aspirin 300 mg daily and eicosapentaenoic acid (EPA) 2000 mg daily, alone and in combination, on urinary biomarker levels and, (2) whether urinary biomarker levels predicted colorectal polyp risk, during participation in the seAFOod polyp prevention trial. Urinary PGE-M and 11-d-TXB₂ were measured by liquid chromatography-tandem mass spectrometry. The relationship between urinary biomarker levels and colorectal polyp outcomes was investigated using negative binomial (polyp number) and logistic (% with one or more polyps) regression models. Despite wide temporal variability in PGE-M and 11-d-TXB₂ levels within individuals, both aspirin and, to a lesser extent, EPA decreased levels of both biomarkers (74% [$P \leq .001$] and 8% [$P \leq .05$] reduction in median 11-d-TXB₂ values, respectively). In the placebo group, a high (quartile [Q] 2-4) baseline 11-d-TXB₂ level predicted increased polyp number (incidence rate ratio [IRR] [95% CI] 2.26 [1.11,4.58]) and risk (odds ratio [95% CI] 3.56 [1.09,11.63]). A low (Q1) on-treatment 11-d-TXB₂ level predicted reduced colorectal polyp number compared to placebo (IRR 0.34 [0.12,0.93] for combination aspirin and EPA treatment) compared to high on-treatment 11-d-TXB₂ values (0.61 [0.34,1.11]). Aspirin and EPA both inhibit PGE-M and 11-d-TXB₂ synthesis in keeping with shared in vivo cyclooxygenase inhibition. Colorectal polyp risk and treatment response prediction by 11-d-TXB₂ is consistent

Abbreviations: AFPPS, Aspirin/Folate Polyp Prevention Study; ANOVA, analysis of variance; BCSP, Bowel Cancer Screening Programme; COX, cyclooxygenase; Cr, creatinine; CRC, colorectal cancer; d, dehydro; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HETE, hydroxyeicosatetraenoate; IMP, Investigational Medicinal Product; IQR, interquartile range; IRR, incidence rate ratio; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LOD, limit of detection; MP, mobile phase; MRM, multiple reaction monitoring; OR, odds ratio; PDR, polyp detection rate; PG, prostaglandin; PGE-M, prostaglandin E metabolite; PUFA, polyunsaturated fatty acid; Q, quartile; RBC, red blood cell; ROC, receiver-operating characteristic curve; TCPS, Tennessee Colorectal Polyp Study; TX, thromboxane; u, urinary; UPLC, ultraperformance liquid chromatography; V, visit.

Ge Sun and Harriett Fuller should be considered joint first authors.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *International Journal of Cancer* published by John Wiley & Sons Ltd on behalf of UICC.

with a role for platelet activation during early colorectal carcinogenesis. The use of urinary 11-d-TXB₂ measurement for a precision approach to colorectal cancer risk prediction and chemoprevention requires prospective evaluation.

KEYWORDS

aspirin, colorectal cancer, eicosapentaenoic acid, prostaglandin, thromboxane

What's new?

In this secondary analysis of the seAFOod polyp prevention trial, the authors report that the putative colorectal cancer chemoprevention agents, aspirin and eicosapentaenoic acid reduce the levels of urinary biomarkers PGE-M and 11-dehydro-TXB₂, a finding compatible with in vivo cyclooxygenase inhibition. Moreover, urinary 11-dehydro-TXB₂ levels predict both the risk of developing colorectal polyps and the chemoprevention efficacy of aspirin and eicosapentaenoic acid, consistent with a role for platelet activation during early colorectal carcinogenesis. The prospective evaluation of urinary 11-dehydro-TXB₂ as a risk and therapeutic response biomarker may help in devising a precision approach to colorectal cancer prevention.

1 | INTRODUCTION

The seAFOod polyp prevention trial was a randomised, double-blind, placebo-controlled, 2 × 2 factorial trial of the colorectal cancer (CRC) chemoprevention efficacy of aspirin 300 mg daily and/or the omega-3 polyunsaturated fatty acid (PUFA) *n*-3C20:5 eicosapentaenoic acid (EPA) 2000 mg daily, for 12 months in 'high risk' (≥5 polyps <10 mm in size, or ≥3 polyps if one ≥10 mm in size) patients undergoing colonoscopy surveillance in the English Bowel Cancer Screening Programme (BCSP).^{1,2}

Although aspirin and EPA did not reduce colorectal polyp incidence, measured as the 'adenoma detection rate' (the % number of individuals with one or more colorectal polyps 12 months after clearance colonoscopy),^{1,2} aspirin use was associated with a significant 22% reduction in overall colorectal polyp risk (measured as mean polyp number per participant),^{1,2} consistent with a large body of evidence supporting the CRC chemoprevention activity of aspirin.³ There was also colorectal site- and polyp type (adenomatous vs serrated polyp)-specific chemoprevention activity of aspirin and EPA; randomisation to aspirin was associated with reduced risk of serrated lesions, unlike EPA treatment, which was associated with a statistically significant reduction in risk of left-sided (distal to the splenic flexure) adenomatous polyps only.^{1,2} Subsequent 'inside the table' analysis of the four treatment groups within the 2 × 2 factorial trial design demonstrated that colorectal polyp risk was significantly lower in participants randomised to combination aspirin and EPA compared to either agent alone.⁴

Aspirin and EPA both inhibit the two cyclooxygenase (COX) isoforms (COX-1 and COX-2), which control the rate-limiting step in the biosynthesis of several prostanoids including prostaglandin (PG) E₂, a lipid mediator with paracrine protumorigenic and immunosuppressive activity, and thromboxane (TX) A₂ that drives platelet aggregation.^{5,6}

Randomised clinical trials have demonstrated that aspirin and EPA reduce levels of the stable urinary metabolite of PGE₂,

11 α -hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (commonly known as PGE-M) in humans with a prior history of colorectal polyps.⁷⁻⁹ High urinary (u) PGE-M levels predicted the detection of 'advanced' colorectal adenomatous polyps and the overall CRC chemoprevention benefit of aspirin in the Nurses' Health Study.¹⁰

The stable urinary metabolite of TXA₂, 11-dehydro (d)-TXB₂ is an established measure of platelet activation¹¹ and of COX-1-dependent antiplatelet activity of aspirin,¹² as well as, to a lesser extent, of EPA.¹³ Aspirin (at 81 mg and 325 mg daily doses) has been demonstrated to reduce 11-d-TXB₂ levels in a secondary analysis of the Aspirin/Folate Polyp Prevention Study (AFPPS).⁹ Colorectal cancer patients display enhanced platelet activation measured by u11-d-TXB₂ levels.¹⁴ However, the use of u11-d-TXB₂ levels for prediction of the anti-CRC activity of aspirin has not been investigated.

Our study aimed to characterise the effect of aspirin and EPA, alone and in combination, on urinary biomarkers of prostanoid synthesis (uPGE-M and u11-d-TXB₂), as well as investigate the role of these urinary biomarkers as predictive biomarkers of colorectal polyp risk and chemoprevention efficacy of aspirin and EPA in 'high risk' individuals who participated in the seAFOod polyp prevention trial.

2 | METHODS

2.1 | The seAFOod polyp prevention trial and biobank

The design and colorectal polyp outcomes of the seAFOod polyp prevention trial have been published in detail.^{1,2} All participants in the seAFOod trial were individuals with 'high risk' colorectal polyp findings (≥5 polyps <10 mm in size, or ≥3 polyps if one ≥10 mm in size), but no synchronous CRC, at clearance screening colonoscopy.^{1,2} This patient population is known to be at elevated risk of metachronous CRC compared to an age- and sex-matched general population.¹⁵

Seven hundred and seven individuals were randomly allocated to treatment with either placebos only, aspirin 300 mg daily, EPA 2000 mg daily, or both active interventions, for 12 months, according to a double-blind, 2 × 2 factorial design.^{1,2}

For this secondary trial analysis, adenomatous and serrated polyps were combined as total colorectal polyps, with ‘advanced’ colorectal polyp defined as ≥10 mm in size and/or with high-grade dysplasia, consistent with current UK colonoscopy surveillance guidelines that acknowledge the malignant potential of serrated lesions, as well as adenomatous polyps.¹⁵

A urine sample was obtained at randomisation prior to starting the trial intervention (visit 1 [V1]), which was at least 7 days after BCSP screening colonoscopy; at 6 months (midtreatment during a scheduled trial visit to obtain more Investigational Medicinal Product [IMP] (visit 4 [V4]); and the day after the final treatment dose, which was the same day as the trial exit colonoscopy (visit 6 [V6]), approximately 12 months after screening colonoscopy.^{2,16} Samples were immediately stored at −20°C locally, prior to transfer on dry ice to the trial Biobank for long-term storage at −80°C.² Sample collection compliance was excellent leading to curation of 78% of expected urine samples in the seAFood trial biobank.²

2.2 | Laboratory methods

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed on an Acquity H-Class Ultra-Performance LC (UPLC) System linked with a Xevo TQ-XS (Waters Corp., Milford, USA) tandem quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode.

PGE-M and 11-d-TXB₂ were extracted simultaneously from urine samples using a solid phase extraction technique. PGE-M-d6 and 11-d-TXB₂-d4 (both 40 µL of a 1 µg/mL solution [Cayman Chemical, Ann Arbor, MI]) were added to 1 mL of urine, which was acidified with 100 µL 1% acetic acid. Solid phase extraction cartridges (Bond Elut C18, 100 mg, 1 mL, Agilent Technologies, Stockport, UK) were pre-conditioned with methanol followed by acidified water (pH 3, acetic acid). The sample was applied to the column and then washed with acidified water followed by heptane. The samples were eluted in 1 mL ethyl acetate and evaporated to dryness using a Genevac EZ-2 evaporation system. Samples were reconstituted in 50 µL 50% mobile phase (MP)A:50% MPB (composition of each MP described below), with 2 µL injected into the UPLC-MS/MS system.

UPLC separation was achieved using an Acquity UPLC BEH C18 Column, 2.1 × 150 mm, 1.7 mm (Waters Corp.), MPA (0.1% [v/v] acetic acid [95 parts]:acetonitrile [5 parts]) and MPB (0.1% [v/v] acetic acid [10 parts]:acetonitrile [90 parts]). Each sample was analysed twice; for PGE-M and for 11-d-TXB₂. An aliquot for PGE-M measurement was separated by a gradient of 98%–91.5% MPA over 10 min at 500 µL/min, while the aliquot for 11-d-TXB₂ measurement was separated with a gradient of 85%–48.3% MPA over 10 minutes at 500 µL/min. Each injection was 20 minutes to allow for column re-equilibration to the appropriate start conditions. The Xevo mass spectrometer was operated in negative

electrospray ionisation mode with a capillary voltage of 2.5 kV, source temperature of 150°C, and desolvation gas flow of 1000 L/h. Cone voltage and collision energy for all analytes were established as 10 V and 15 V respectively. MRM channels were set as PGE-M (m/z 327 > 291.3 and 327 > 309.40), the internal standard PGE-M-d6 (m/z 333 > 297.3 and 333 > 315.4), 11-d-TXB₂ (m/z 367.2 > 305.1 and 367.2 > 349.2) and the internal standard 11-d-TXB₂-d4 (m/z 371.2 > 309.1 and 371.2 > 353.2).

PGE-M and 11-d-TXB₂ were quantified against their respective internal standard with a calibration range 0.1–50 ng/mL. The limit of detection (LOD) for both analytes was 20 pg/mL, which was the concentration assigned to any sample with undetectable u11-d-TXB₂.

The urinary creatinine (Cr) concentration in mg/ml was measured using a creatinine colorimetric assay (Cayman Chemical, Ann Arbor, MI). All uPGE-M and u11-d-TXB₂ data are expressed per mg creatinine.

Red blood cell (RBC) membrane EPA content was measured by LC-MS/MS.^{1,2} Fatty acid profiles in RBC membranes in seAFood trial participants have been reported previously.^{1,2} Data are expressed as the % of total fatty acids.

2.3 | Statistical analysis

Baseline urinary biomarker data were not normally distributed. Therefore, data were logarithmically transformed prior to parametric univariate (*t* test/ANOVA) and multivariate regression analysis of differences in urinary values related to clinical characteristics.

The effect of the trial interventions on uPGE-M and u11-d-TXB₂ levels is reported as the percentage change at V4 or V6 from the corresponding V1 value per participant, as well as the absolute analyte concentration at individual time-points.⁷ Comparisons between the four trial treatment groups were performed using the Chi-squared test (for the % of participants with a reduction in biomarker level at V4 or V6 compared to V1) or the Kruskal-Wallis test (with post hoc Bonferroni testing) for uPGE-M and u11-d-TXB₂ concentrations. Comparison of the treatment effect of EPA and aspirin, alone and in combination, at V4 and V6 was carried out with the Wilcoxon rank sum test.

The relationship between the *baseline* uPGE-M or u11-d-TXB₂ level at V1 and colorectal polyp recurrence in the placebo group only, as well as the relationship between the *on-treatment* uPGE-M or u11-d-TXB₂ level (as the absolute value at V4 or the absolute difference between the V1 and V4 level) and colorectal polyp number after any active treatment, was investigated using negative binomial (for colorectal polyp number) or logistic (for the polyp detection rate [PDR; the % number of individuals with one or more colorectal polyps], and the presence or absence of ‘high risk’ findings [five or more colorectal polyps of any size, or two or more colorectal polyps, if at least one has ‘advanced’ characteristics {15}]) regression models. Both models compared urinary biomarker value quartiles. A low uPGE-M or u11-d-TXB₂ level was defined as being in the lowest quartile (Q1) and urinary biomarker values in Q2–4 were classified as ‘high’

in both models. Consistent with the primary seAFOod trial analysis, repeat colonoscopy at baseline was included as a co-variate and data were adjusted for the BCSP research site.¹ Sex was included as a term given the consistent, strong relationship between male sex and colorectal polyp recurrence in previous colonoscopic surveillance studies.^{17,18}

The performance characteristics of a previously published threshold uPGE-M value (5.34 ng/mg), which has been reported to distinguish individuals with reduced risk of ‘advanced’ polyp,⁹ for detection of one or more polyps in the seAFOod trial placebo arm was derived by bootstrapping ($\times 1000$) for derivation of a receiver-operating characteristic curve (ROC).

All statistical analysis was performed using R studio (version 2021.09.0).

3 | RESULTS

3.1 | Urinary biomarkers of PGE₂ synthesis and platelet activation in ‘high risk’ colorectal polyp patients

The distribution of urine samples collected at the three trial visits from seAFOod trial participants is described in Table S1. Baseline (pretreatment) uPGE-M data were available for 601 (85%) and baseline (pretreatment) u11-d-TXB₂ data were available for 471 (67%) trial participants. Ninety-nine individuals did not provide a V1 sample. Seven V1 urine samples were not measured for either analyte because of a storage temperature deviation ($> -20^{\circ}\text{C}$) at the research site. An additional 130 V1 samples had a quantifiable uPGE-M level, but no corresponding u11-d-TXB₂ value, due to absence of a clear, quantifiable chromatographic peak.

Overall, the median (interquartile range [IQR]) uPGE-M level at entry to the seAFOod trial was 7.6 (4.5–12.5) ng/mg (corresponding mean [SD] value 9.9 [9.9] ng/mg), with a baseline median u11-d-TXB₂ level of 538 (399–770) pg/mg (corresponding mean value 674 [561] pg/mg). Levels of uPGE-M and u11-d-TXB₂ stratified for individual clinical characteristics are described in Table 1.

Consistent with previous reports, pretreatment uPGE-M levels were higher in men than women.¹⁹ We also observed that current and former tobacco smokers had elevated baseline uPGE-M levels compared to individuals who had never smoked.²⁰ Individuals with a diagnosis of diabetes had significantly higher baseline uPGE-M levels than nondiabetics.^{7,10} We also observed a relationship between increasing alcohol intake and uPGE-M levels (Table 1).

There was no significant difference in pretreatment u11-d-TXB₂ levels between men and women in the seAFOod trial cohort of individuals, who had recently had multiple colorectal polyps removed (Table 1). Current and ex-smokers had higher levels of u11-d-TXB₂ than never smokers, in keeping with previous reports^{21,22} (Table 1).

At baseline, prior to starting any trial intervention, there was a weak ($R = .29$, $P < .0001$), relationship between the uPGE-M level and u11-d-TXB₂ level in individual participants (Figure S1).

3.2 | The effect of EPA and aspirin on uPGE-M levels

The effect of EPA and aspirin treatment, alone and in combination, on uPGE-M levels is presented as the % change from baseline (V1) (Figure 1A), as well as the uPGE-M concentration (Figure 1B), at 6 months (V4) and 12 months (V6). In general, there was marked variability in uPGE-M levels over time within individuals, which was apparent from the placebo arm of the seAFOod trial (Figure 1A). After treatment with EPA alone for 6 months, there was a larger proportion of trial participants with a lower uPGE-M level at V4 than the corresponding V1 level (59%) in comparison with the placebo group (45%; Figure 1A and Table 2). The median (interquartile range [IQR]) uPGE-M concentration at V4 in those allocated EPA was 6.9 (3.5–10.9) ng/mg, compared to 9.1 (5.3–13.4) ng/mg in the placebo group ($P \leq .01$; Figure 1B and Table 2). Aspirin treatment was associated with a larger treatment effect on uPGE-M levels than EPA with corresponding values of 66% and 6.1 (3.7–10.2) ng/mg at V4 ($P \leq .05$ and $\leq .001$, respectively, compared to placebo; Figure 1A,B and Table 2). Combination EPA and aspirin treatment was not associated with a larger treatment effect on uPGE-M than aspirin treatment alone with 66% of individuals allocated to both agents displaying a lower V4 value than the corresponding V1 level and a median uPGE-M concentration of 5.8 (3.9–11.4) ng/mg (Figure 1B and Table 2). At 12 months, the treatment effect of EPA and aspirin, alone and in combination, was maintained compared to V4, with no statistically significant difference in either the % of participants with a lower uPGE-M level compared to baseline or the uPGE-M concentration between V4 and V6 values (Figure 1A,B and Table 2).

In an additional analysis, we assessed changes in uPGE-M levels based on threshold values used in previous publications.^{7,9,10} Firstly, we dichotomized % change values at V4 and V6 based on a reduction in uPGE-M concentration of 33.5%, which had been used by Drew and colleagues as a cut-off value, below which there may be reduced ‘advanced’ colorectal polyp risk based on Nurses’ Health Study data.¹⁰ Similar treatment effects were observed at V4, with more participants allocated to combination aspirin and EPA displaying a $>33.5\%$ reduction in uPGE-M level compared to placebo ($P \leq .001$; Figure 1A and Table 2). However, there was no discernable change in the % number of individuals with a $>33.5\%$ reduction in uPGE-M at V6 compared to V1 for any treatment group (Figure 1A and Table 2). Secondly, we analysed the uPGE-M data according to a threshold uPGE-M value of 5.34 ng/mg that has been reported to be the level below which participants had reduced risk of ‘advanced’ adenoma in the AFPPS trial.⁹ There was a larger proportion of individuals (42%) that received combination aspirin and EPA treatment who had a uPGE-M

TABLE 1 Comparison of pretreatment uPGE-M and u11-d-TXB₂ levels according to clinical characteristics of seAFOod trial participants.

	n	uPGE-M (ng/mg Cr) ^a	Univariate P ^b	Multivariate P ^c	n	u11-d-TXB ₂ (pg/mg Cr) ^a	Univariate P ^b
Overall trial population	601	7.6 (4.5-12.5)			471	538 (399-770)	
Sex							
Male	480	8.1 (4.9-13.3)	<.001	<.0001	378	523 (396-752)	.56
Female	121	5.1 (3.2-9.0)			93	574 (412-794)	
Body mass index (BMI)							
Underweight (<18.5 Kg/m ²)	3	5.0 (3.7-8.2)	.36	-	3	468 (439-1466)	.80
Normal (≥18.5 to <25 Kg/m ²)	106	7.5 (4.3-12.3)			92	533 (378-806)	
Overweight (≥25 to <30 Kg/m ²)	263	8.1 (4.7-13.2)			166	557 (389-758)	
Obese (≥30 Kg/m ²)	227	7.3 (4.2-11.6)			209	536 (433-759)	
Diabetes							
No	535	7.3 (4.4-12.2)	.002	<.0001	422	528 (391-747)	.25
Yes	66	9.8 (6.3-15.6)			49	618 (463-1014)	
Tobacco smoking							
Never	213	6.7 (3.9-10.8)	.002	.005	159	490 (387-642)	.01
Ever	293	7.6 (4.6-12.7)			234	537 (399-798)	
Current	95	9.1 (5.8-14.1)			78	706 (470-1072)	
Alcohol intake							
None	94	6.1 (3.6-10.1)	<.001	<.001	70	494 (381-699)	.12
1-7 units/week	205	5.9 (3.8-10.2)			160	536 (411-716)	
8-21 units/week	175	8.9 (5.4-12.6)			141	528 (405-835)	
≥22 units/week	125	10.1 (6.0-16.3)			98	604 (417-800)	

^aData are presented as the median and interquartile range.

^bTwo-sample *t* test for binary variables or ANOVA for multiclass variables on log-transformed data.

^cVariables that were statistically significant by univariate testing were taken through to a multivariate regression model. BMI and alcohol intake were not available for two participants with a PGE-M value. The BMI was missing for one participant who had a baseline 11-d-TXB₂ value and alcohol intake was missing for two participants who had a baseline 11-d-TXB₂ value.

concentration <5.34 ng/mg at V4 compared to the placebo group (25%; $P \leq .05$) (Figure 1B and Table 2). There was no statistically significant difference from the placebo group in the % of individuals below -33.5% and 5.34 ng/mg thresholds in the three active treatment groups at V6 (Figure 1 and Table 2).

3.3 | The effect of EPA and aspirin on u11-d-TXB₂ levels

Marked variability in u11-d-TXB₂ levels over time within individuals was apparent in participants in the placebo arm of the seAFOod trial (Figure 2A). There was a modest treatment effect of EPA (approximately 8% reduction) on u11-d-TXB₂ levels at V4, which was absent at V6 (Figure 2A,B and Table 2). Consistent with dose-dependent inhibitory activity of EPA on COX-1, there was an inverse relationship between the RBC membrane EPA content and the corresponding u11-d-TXB₂ level in seAFOod trial participants who did not receive aspirin ($r = -.27$; $P < .001$), which was most pronounced in those that were randomised to active EPA (Figure S2). A similar relationship was not evident between the RBC membrane EPA level and the uPGE-M concentration in the same trial participants (data not shown).

By contrast, there was a marked (approximately 74%) reduction in u11-d-TXB₂ concentration at V4 in participants allocated to aspirin alone compared to the placebo group (Figure 2A,B and Table 2). The proportion of individuals in the aspirin group with a lower u11-d-TXB₂ level at V4 compared to baseline (V1) was 90% compared to 38% in the placebo group ($P \leq .001$; Figure 2A and Table 2). There were lower u11-d-TXB₂ levels in the aspirin group (median [IQR] u11-d-TXB₂ concentration 133 [27-266] pg/mg) compared to those allocated to placebo (645 [482-947] pg/mg) at V4 ($P \leq .001$; Figure 2B and Table 2). There was no evidence of an additive relationship between aspirin and EPA after 6 months on-trial in individuals randomised to combination treatment (Figure 2A,B and Table 2).

After 12 months on treatment (V6), there was a marked reduction in the effect of aspirin treatment alone (but not for EPA) on u11-d-TXB₂ levels at V6 compared to the treatment effect at V4 (Figure 2A,B and Table 2). However, u11-d-TXB₂ levels remained statistically significantly lower in the aspirin group at V6 (median [IQR] 329 [198-565] pg/mg) compared to the placebo group (629 [413-895]; $P \leq .001$). Similar findings were apparent in the combination aspirin and EPA arm with a significant reduction in the treatment effect on u11-d-TXB₂ levels at V6 compared to V4 (Figure 2A,B and Table 2).




FIGURE 1 Legend on next page.

TABLE 2 Comparison of the change from the baseline (V1) value and absolute concentration of uPGE-M and u11-d-TXB₂ at V4 and V6 between seAFood trial treatment groups.

uPGE-M	Placebo	EPA	Aspirin	Aspirin + EPA	P value
V1					
Number of participants	150	152	151	148	
Median (IQR) uPGE-M concentration (ng/mg Cr)	8.4 (5.2-12.7)	7.4 (4.4-12.2)	6.9 (4.0-12.3)	7.6 (4.6-12.4)	.42
Number (%) with uPGE-M concentration <5.34 ng/mg Cr	39 (26)	53 (35)	57 (38)	50 (34)	.16
V4					
Number of participants	126	114	128	119	
Median (IQR) uPGE-M concentration (ng/mg Cr)	9.1 (5.3-13.4)	6.9 (3.5-10.9)**	6.1 (3.7-10.2)***	5.8 (3.9-11.4)*	<.001 ^{a,b}
Number (%) with any reduction in uPGE-M	57 (45)	67 (59)	84 (66)*	79 (66)**	.002 ^c
Number (%) with >33.5% reduction in uPGE-M	25 (20)	35 (31)	44 (34)	51 (43)***	.001 ^c
Number (%) with uPGE-M concentration <5.34 ng/mg Cr	32 (25)	48 (42)	53 (41)	50 (42)*	.01 ^c
V6					
Number of participants	109	103	96	97	
Median (IQR) uPGE-M concentration (ng/mg Cr)	6.9 (4.5-12.9)	6.1 (3.4-11.1)	6.9 (3.3-10.8)	5.7 (3.2-8.7)*	.07 ^{a,b}
Number (%) with any reduction in uPGE-M	61 (56)	55 (53)	55 (57)	68 (70)	.08 ^c
Number (%) with >33.5% reduction in uPGE-M	36 (33)	32 (31)	42 (44)	39 (40)	.20 ^c
Number (%) with uPGE-M concentration <5.34 ng/mg Cr	39 (36)	43 (42)	38 (40)	46 (47)	.39 ^c
u11-d-TXB ₂	Placebo	EPA	Aspirin	Aspirin + EPA	P value
V1					
Number of participants ^d	121	115	115	113	
Median (IQR) u11-d-TXB ₂ concentration (pg/mg Cr)	542 (400-818)	559 (419-736)	504 (388-736)	550 (400-782)	.45
V4					
Number of participants ^e	97	82	93	87	
Median (IQR) u11-d-TXB ₂ concentration (pg/mg Cr)	645 (482-947)	515 (335-776)*	133 (27-266)***	132 (30-267)***	<.001 ^{a,b}
Number (%) with any reduction in u11-d-TXB ₂	37 (38)	50 (61)*	84 (90)***	80 (92)***	<.001 ^c
V6					
Number of participants ^e	87	78	60	70	
Median (IQR) u11-d-TXB ₂ concentration (pg/mg Cr)	629 (413-895)	567 (404-802)	329 (198-565)***,¶	272 (151-435)***,¶	<.001 ^{a,b}
Number (%) with any reduction in u11-d-TXB ₂	41 (47)	37 (47)	43 (72)*†	58 (83)***	<.001 ^c

^aUrinary biomarker concentrations were compared to the Kruskal-Wallis test.

^bPost hoc intergroup comparisons vs the placebo group were significant at the following levels; * $P \leq .05$, ** $P \leq .01$, *** $P \leq .001$.

^cThe number (%) of participants was compared to a Chi-squared test.

^dThere were seven participants with a V1 u11-d-TXB₂ value, two participants with paired V1-V4 u11-d-TXB₂ values and one participant with a paired V1-V6 u11-d-TXB₂ value that had missing data on treatment allocation and were excluded.

^euPGE-M and u11-d-TXB₂ levels at V1, V4 and V6 in individual treatment groups were compared using the Wilcoxon rank sum test. There was no statistically significant difference between V4 and V6 values except for the aspirin effect on u11-d-TXB₂ levels at V6 compared to V4 (†denotes $P < .01$, ¶ $P < .001$).

3.4 | The relationship between treatment effects on uPGE-M and u11-d-TXB₂ levels at participant-level

There was evidence of a weak correlation between the change in uPGE-M from V1 and the respective change in u11-d-TXB₂

concentration from baseline in each participant at V4 and V6 (analysed as the absolute change in analyte concentration and as the % change from baseline) in each of the trial four treatment groups (Figure S3), in keeping with the shared COX-inhibitory properties of aspirin and EPA.

FIGURE 1 The percentage change in uPGE-M level (A) and absolute pretreatment and on-treatment PGE-M levels (B) at 6 months (V4) and 12 months (V6) in seAFood trial participants according to treatment group. The x axis denotes the number of participants in each group with paired uPGE-M data. In (A), paired V1 and later time-point data are presented in parallel, in order to highlight wide within-individual variation in PGE-M levels. Individual treatment group summary data and statistical comparisons are presented in Table S2. The dashed line in (A) denotes the 33.5% reduction threshold previously considered to be associated with reduced risk of 'advanced' adenoma.¹⁰ The dashed line in (B) denotes a uPGE-M value of 5.34 ng/mg below which participants in the AFPPS trial had reduced risk of 'advanced' adenoma.⁹




FIGURE 2 The percentage change in u11-d-TXB₂ level (A) and absolute pretreatment and on-treatment u11-d-TXB₂ levels (B) at 6 months (V4) and 12 months (V6) in seAFood trial participants according to treatment group. The x axis denotes the number of participants in each group with paired u11-d-TXB₂ data. In (A), paired V1 and later time-point data are presented in parallel, in order to highlight wide within-individual variation in 11-d-TXB₂ levels. Individual treatment group summary data and statistical comparisons are presented in Table S2.

3.5 | Factors associated with reduced treatment effects on urinary biomarkers at 12 months

We postulated that the reduction in overall treatment effect on u11-d-TXB₂ levels at V6 compared to V4 could be explained by reduced treatment compliance at the later time-point. We previously reported overall capsule and tablet compliance in the seAFOod trial, which were both excellent,¹ but we were unable to distinguish accurately between compliance levels at V4 and V6. However, trial participants were asked whether they were still taking capsules and tablets at each trial visit. Therefore, we performed a 'per-protocol' analysis by excluding individuals who reported not taking capsules and/or tablets at V4 and/or V6 (Table S2 and Figure S4). There was no significant change in the effect of either EPA or aspirin on uPGE-M or u11-d-TXB₂ levels at V4 or V6 time-points compared to the full analysis, which had included all participants who provided paired urine samples for urinary biomarker measurements (Table 2 and Figures 1 and 2). Of note, there was no diminution of the reduction in treatment effect of aspirin on u11-d-TXB₂ levels at V6 compared to V4 after exclusion of those that had stopped taking trial treatment (Table S2 and Figure S4). This suggests that reduced IMP use at V6 does not completely explain the loss of the treatment effect of aspirin on u11-d-TXB₂ levels over time.

We also noted that there were more participants with a large increase in u11-d-TXB₂ concentration from baseline values at 12 months compared to the 6-month data, even in the groups who were allocated to aspirin. It has previously been reported that the colonoscopy procedure is associated with immediate, but transient, bacterial endotoxaemia and an increase in plasma TXB₂ levels that returned to baseline levels by 24 hours postprocedure in some individuals.²³ The seAFOod trial protocol stipulated that a urine sample was collected on the same day as (after) the trial exit colonoscopy (the day after the final IMP doses). However, a few participants submitted a urine sample three or more days after the colonoscopy for practical

reasons, which gave us an opportunity to investigate whether the proximity to colonoscopy was associated with higher u11-d-TXB₂ levels at V6 in some individuals. The u11-d-TXB₂ concentration in urine samples provided by participants in the placebo group on the same day as the colonoscopy (median [IQR] 617 [431-857] pg/mg) was higher than the u11-d-TXB₂ levels in urine samples provided ≥ 3 days after the colonoscopy from individuals from all treatment groups, who last took IMP at least 4 days previously (428 [309-555] pg/mg; $P = .01$; Mann-Whitney U test; Figure S5A). However, there was no significant difference in uPGE-M concentration in V6 samples collected on the same day as (7.1 [4.6-11.4] ng/mg) vs ≥ 3 days after colonoscopy (7.7 (6.1-9.0); $P = .41$; Student's t test on log-transformed data; Figure S5B). This suggests that the proximity to a colonoscopy of the V6 sample collection may contribute to the difference between u11-d-TXB₂ levels observed at V6 compared to V4 even in those allocated to aspirin, possibly reflecting increased non-platelet TXA₂ synthesis associated with the colonoscopy procedure and/or the bowel preparation. Given the reduction in treatment effect of EPA and aspirin on urinary analyte levels at V6 compared to V4 (noting that last IMP dosing was the day before V6 urine sampling) and the confounding effect of the proximity to colonoscopy, we restricted further analyses of the predictive value of uPGE-M and u11-d-TXB₂ levels on colorectal polyp outcomes in the seAFOod trial to urinary analyte values measured at 6 months (V4).

3.6 | The relationship between uPGE-M and u11-d-TXB₂ levels with colorectal polyp outcomes

Analysis of colorectal polyp outcomes in seAFOod trial participants, who were allocated to placebos only, allowed us to investigate whether urinary biomarker levels at trial entry (V1) were predictive of colorectal polyp outcomes 12 months after clearance colonoscopy, independently of any intervention.

TABLE 3 The relationship between the baseline urinary biomarker value and colorectal polyp outcomes at seAFOod trial exit colonoscopy in participants randomised to placebos only.

	Colorectal polyp number		PDR (% of individuals with one or more polyps)		'High risk' findings	
	n	IRR ^a (95% CI) ^b	Cases/total (n)	Odds ratio (95% CI) ^b	Cases/total (n)	Odds ratio (95% CI) ^b
PGE-M (ng/mg creatinine)						
Q1 (0.45-4.52)	25	Reference	17/25	Reference	1/25	Reference
Q2 (4.53-7.67)	34	1.17 (0.44, 3.17)	20/34	0.70 (0.24, 2.04)	4/33	3.43 (0.37, 31.61)
Q3 (7.68-12.63)	39	1.08 (0.41, 2.88)	22/39	0.67 (0.31, 1.44)	2/39	1.19 (0.09, 16.11)
Q4 (12.64-164.65)	35	2.59 (0.95, 7.05)	23/35	1.03 (0.37, 2.83)	4/32	3.40 (0.32, 35.56)
11-d-TXB ₂ (pg/mg creatinine)						
Q1 (9-397)	29	Reference	14/29	Reference	1/28	Reference
Q2 (398-530)	28	3.18 (1.54, 6.56)	22/28	3.56 (1.09, 11.63)	2/26	2.10 (0.25, 17.97)
Q3 (531-769)	19	2.32 (1.03, 5.21)	14/19	2.66 (0.69, 10.30)	0/18	0 (0, 0)
Q4 (770-6530)	30	2.26 (1.11, 4.58)	18/30	1.78 (0.72, 4.43)	3/28	3.16 (0.36, 27.94)

Note: Bold signifies statistically significant values.

^aIncidence rate ratio.

^bRegression models were adjusted for sex and repeat colonoscopy at baseline.

TABLE 4 The relationship between the on-treatment urinary biomarker level and total colorectal polyp number after 12 months of treatment with EPA and aspirin, alone or in combination, during the seAFOod polyp prevention trial.

PGE-M	Placebo ^a	EPA			Aspirin			Aspirin + EPA		
	n	n	IRR ^b (95% CI) ^c	P	n	IRR ^b (95% CI) ^c	P	n	IRR ^b (95% CI) ^c	P
All participants (n = 435)	114	100	0.74 (0.47, 1.17)	.20	113	0.89 (0.57, 1.38)	.59	108	1.03 (0.66, 1.62)	.89
Low PGE-M (<4.12) ^d (n = 107)	17	31	0.38 (0.12, 1.17)	.10	30	0.39 (0.13, 1.20)	.10	29	0.40 (0.13, 1.23)	.11
High PGE-M (≥4.12) ^d (n = 328)	97	69	0.81 (0.49, 1.35)	.43	83	1.04 (0.64, 1.69)	.87	79	1.30 (0.80, 2.12)	.30

11-d-TXB ₂	Placebo ^a	EPA			Aspirin			Aspirin + EPA		
	n	n	IRR ^b (95% CI) ^c	P	n	IRR ^b (95% CI) ^c	P	n	IRR ^b (95% CI) ^c	P
All participants (n = 316)	87	71	1.25 (0.77, 2.02)	.37	77	0.83 (0.52, 1.33)	.45	81	0.58 (0.36, 0.92)	.02
Low 11-d-TXB ₂ (<107) ^d (n = 84)	6	4	0.27 (0.06, 1.16)	.08	37	0.39 (0.14, 1.08)	.07	37	0.34 (0.12, 0.93)	.04
High 11-d-TXB ₂ (≥107) ^d (n = 232)	81	67	1.37 (0.81, 2.33)	.24	40	1.08 (0.59, 2.01)	.80	44	0.61 (0.34, 1.11)	.11

^aReference group.

^bIncidence rate ratio.

^cThe regression model was adjusted for sex and repeat colonoscopy at baseline.

^dLow PGE-M/11-d-TXB₂ = quartile 1; High PGE-M/11-d-TXB₂ = quartile 2, 3 and 4 of V4 (6 months on treatment) values.

The baseline uPGE-M value was not associated with an increased colorectal polyp number or PDR in seAFOod trial participants allocated to placebos only (Table 3). There were only a small number of participants with 'high risk' polyp findings in each baseline uPGE-M quartile limiting interpretation of this endpoint (Table 3). There was no difference in total colorectal polyp risk in placebo group participants according to the threshold uPGE-M value of 5.34 ng/mg (Table S3A), below which risk of 'advanced' adenoma was lower in the AFPPS trial.⁹ The sensitivity and specificity of the 5.34 ng/mg cut-off for all colorectal polyp detection was 92% and 9%, respectively (area under ROC 0.51; positive predictive value 62%). There were only 4 advanced colorectal polyps found in individuals randomised to placebos only in the seAFOod trial so that a meaningful analysis of advanced polyp prediction was not possible.

By contrast, in comparison with seAFOod trial participants with the lowest quartile baseline u11-d-TXB₂ levels, individuals with a higher baseline u11-d-TXB₂ level (Q2-4) had an increased number of polyps at subsequent colonoscopy (incidence rate ratio [IRR] [95% confidence interval (CI)] 2.26 [1.11, 4.58] for Q4) and also a higher PDR, which reached statistical significance for Q2 (odds ratio [OR] [95% CI] 3.56 [1.09, 11.63]; Table 3).

Next, we investigated the ability of the on-treatment (V4) urinary biomarker level to predict colorectal polyp number in seAFOod trial participants in each of the three active intervention groups. We defined a 'low' urinary biomarker level as any value less than or equal to the Q1 value, as opposed to concentrations in Q2-4, which were defined as 'high'. The on-treatment uPGE-M concentration did not predict colorectal polyp number for any of the three active treatment groups compared to placebo, although, in all three active treatment groups, individuals with a low uPGE-M level after 6 months' treatment had a lower, but not statistically significant, IRR value than participants with high uPGE-M during treatment (Table 4).

For patients who had a low u11-d-TXB₂ level at 6 months (V4), all three active treatments led to a decrease in the number of

colorectal polyps at colonoscopy at 12 months compared to placebo (Table 4 and Figure S6). This reduction was statistically significant in patients who received a combination of aspirin and EPA (IRR 0.34 [0.12, 0.93]). In contrast, for individuals with a high u11-d-TXB₂ level at V4 during active treatment, there was no reduction in colorectal polyp number at trial exit colonoscopy (Table 4 and Figure S6).

We also explored whether the change in urinary biomarker level from baseline during treatment was predictive of colorectal polyp outcomes (Table S4). The change in uPGE-M level at V4 from V1 during active treatment did not predict colorectal polyp number (Table S4). There was no difference in colorectal polyp risk in the active treatment groups stratified using the 33.5% reduction threshold identified by the Nurses' Health as being associated with reduced 'advanced' colorectal polyp risk (Table S3B).¹⁰

However, the highest quartile of difference between V1 and V4 u11-d-TXB₂ levels (effectively those individuals with an increase in u11-d-TXB₂ level during active treatment in the seAFOod trial; Table S4) was associated with increased colorectal polyp number compared to those participants with the lowest quartile u11-d-TXB₂ level change (equivalent to the largest on-treatment reduction). This relationship only attained statistical significance for analysis of the three treatment groups combined due to the small size of the higher quartiles of u11-d-TXB₂ level differences in the individual active treatment groups (Table S4).

4 | DISCUSSION

In a secondary analysis of the seAFOod polyp prevention trial, we report that aspirin 300 mg daily and, to a lesser extent, EPA 2000 mg daily both reduce levels of the stable urinary prostanoid metabolites PGE-M and 11-d-TXB₂, during dosing for up to 12 months, compatible with in vivo COX-1 and COX-2 inhibition. Importantly, we demonstrate that the u11-d-TXB₂ level predicts subsequent colorectal polyp

development independently of any chemoprevention, compatible with an emerging link between platelet activation and colorectal carcinogenesis.²⁴ Another key finding is that u11-d-TXB₂ suppression during treatment with aspirin and EPA predicts their chemoprevention efficacy, as measured by colorectal polyp recurrence.

Pretreatment levels of uPGE-M in seAFOod trial participants were comparable to concentrations reported in similar populations undergoing colonoscopy and polypectomy.⁷⁻⁹ The relationship between male sex, tobacco smoking (current and previous), BMI and elevated uPGE-M levels in the seAFOod trial population is consistent with the existing literature.^{10,19,20}

Baseline levels of u11-d-TXB₂ were higher than levels detected in AFPPS participants (which were approximately 200-300 pg/mg creatinine⁹), but lower than those reported in the ASPIRED trial of individuals who had undergone colorectal polyp clearance in the past 9 months (median 1700 pg/mg creatinine).⁷ Consistent with AFPPS findings and several studies of individuals with cardiovascular risk factors, we also noted higher u11-d-TXB₂ levels in current smokers compared to nonsmokers.^{25,26} However, we did not demonstrate a sex-difference in u11-d-TXB₂ levels, unlike AFPPS.⁹ Notwithstanding methodological differences in measurement of stable urinary TXB₂ metabolites and differences in demographics between different studies, our data support the assertion that platelet activation (as measured by u11-d-TXB₂ levels) in individuals, who have developed one or more colorectal polyps and then undergone clearance colonoscopy, is similar to levels detected in populations which have similar cardiovascular/cancer risk factors such as obesity and diabetes.²⁷ There are limited data on u11-d-TXB₂ levels in CRC patients, but a small study (n = 10) concluded that u11-d-TXB₂ excretion in CRC patients (median 1000 pg/mg creatinine) was significantly higher than matched controls that had similar clinical characteristics to the seAFOod trial population.¹⁴ Comparison with the median (IQR) u11-d-TXB₂ level of 1060 (667-1558) pg/mg in 192 Add-Aspirin trial participants, who had undergone surgical resection of a stage II or III CRC, suggests that colorectal polyp patients display lower u11-d-TXB₂ levels than CRC patients even after primary CRC therapy.²⁸

The effect of long-term (12 months) EPA and aspirin treatment on uPGE-M excretion was modest, on a background of wide variability in uPGE-M levels over time within individuals. A small (<10%) reduction in uPGE-M concentration during treatment with a mixed omega-3 PUFA formulation (1395 mg EPA and 1125 mg docosahexaenoic acid [DHA] daily) for 6 months in 70 patients with a history of colorectal polyps (the Tennessee Colorectal Polyp Study [TCPS]) has been reported previously.⁸ Our data also concur with the effect of aspirin 81 mg (n = 57) or 325 mg (n = 54) daily vs placebo (n = 58) on uPGE-M levels at a single 3 month time-point in the ASPIRED trial.⁷ In the AFPPS, on-treatment urine samples were obtained at variable times during the third intervention year and revealed a similar reduction in uPGE-M concentration in individuals randomised to aspirin 81 mg or 325 mg daily compared to our seAFOod trial data.⁹ In seAFOod trial participants, the treatment effect of EPA and aspirin on uPGE-M levels was maintained up to 12 months, unlike the TCPS trial, which demonstrated a diminution of the treatment effect of mixed

omega-3 PUFAs on uPGE-M levels at 6 months compared to 3 months, despite maintenance of high RBC omega-3 PUFA levels.⁸

The effect of aspirin 300 mg daily on u11-d-TXB₂ excretion in individuals with a history of multiple colorectal polyps adds to the substantial literature on u11-d-TXB₂ as a biomarker of platelet inhibition by aspirin.²⁷ The effect size of aspirin 300 mg daily on u11-d-TXB₂ levels (a 74% reduction) in seAFOod trial participants was similar to that observed during treatment with aspirin 100 and 300 mg daily for at least 3 months in Add-Aspirin trial participants.²⁸ The precise contribution of platelet- and nonplatelet-dependent TXB₂ synthesis in seAFOod trial participants is unclear. However, the highly variable u11-d-TXB₂ levels detected in individuals, who were randomised to active aspirin (acknowledging likely variable treatment compliance), argues that there is a significant contribution to TXB₂ synthesis from nonplatelet sources, in which COX isoform inhibition by aspirin is incomplete, as reported by Lanas et al in familial adenomatous polyposis patients.²⁹ The reduction in u11-d-TXB₂ suppression at 12 months compared to 6 months in aspirin users is most likely to be due to reduced tablet compliance over time on trial but the effect of stopping IMP the day before urine and blood sampling, as per seAFOod trial protocol, is also likely to be a contributing factor.

Our data are consistent with the modest antiplatelet activity of EPA.³⁰ Importantly, the level of tissue EPA incorporation (measured by RBC membrane levels) was related to the u11-d-TXB₂ level, particularly in EPA users. The relationship between dietary omega-3 PUFA intake, tissue omega-3 PUFA levels and u11-d-TXB₂ excretion should be explored further in order to delineate the link between dietary omega-3 PUFA intake and platelet activation. The absence of an additive relationship between aspirin and EPA on u11-d-TXB₂ levels in seAFOod trial participants that were randomised to both active treatments is consistent with several platelet function studies [reviewed in 30].

A strength of our study was the ability to test the predictive value of uPGE-M and u11-d-TXB₂ for determining subsequent colorectal polyp risk in the placebo group, as well as for testing the utility of on-treatment urinary biomarker levels for therapeutic response prediction, using seAFOod trial colonoscopy outcomes.

There was no statistically significant relationship between the baseline uPGE-M level and colorectal polyp outcomes 12 months later. However, a higher baseline u11-d-TXB₂ level did predict increased colorectal polyp risk (as measured by colorectal polyp number) at seAFOod trial exit colonoscopy 12 months later compared to individuals with a low (Q1) u11-d-TXB₂ level. The AFPPS reported null findings for the relationship between both uPGE-M and u11-d-TXB₂ levels (measured after 3 years on-trial) and colorectal polyp occurrence (reported as the PDR) in the placebo group; however, colorectal polyp number outcomes were not described.⁹ Using a similar approach to stratify individuals as having a high vs low u11-d-TXB₂ level, Rade and colleagues have reported that a high u11-d-TXB₂ level predicts all-cancer mortality, irrespective of aspirin use, in a large longitudinal cohort study.²⁶ A prospective validation study of the relationship between the u11-d-TXB₂ level and subsequent colorectal polyp outcomes is now required to determine the role of the baseline u11-d-TXB₂ concentration as a risk biomarker.

When we investigated the relationship between the on-treatment urinary biomarker value (at 6 months) and subsequent colorectal polyp number detected at colonoscopy, we observed a consistent reduction in colorectal polyp risk in individuals with a low uPGE-M and u11-d-TXB₂ level compared to those with higher uPGE-M and u11-d-TXB₂ values. This relationship was statistically significant only for individuals randomised to combination aspirin and EPA, which was the treatment group that displayed the largest reduction in colorectal polyp risk in the secondary individual treatment group analysis of the seAFOod trial.^{1,4} There was no relationship between the on-treatment u11-d-TXB₂ level and colorectal polyp outcomes in the secondary AFPPS analysis.⁹ However, the timing of the urine sampling (in relation to the colonoscopic outcomes) was variable in AFPPS and no data were provided about treatment compliance at the time of sampling.⁹

We also show that those participants who displayed an increase in u11-d-TXB₂, despite randomisation to an active treatment arm (likely due to poor treatment compliance), had increased colorectal polyp risk consistent with absence of the antineoplastic activity of aspirin. A prospective study of u11-d-TXB₂ levels in patients before and during aspirin treatment in future polyp prevention trials should be considered in order to strengthen evidence that the absolute level or change from the baseline value of u11-d-TXB₂ predicts colorectal polyp (and CRC) prevention by aspirin, as well as delineate clinically meaningful cut-off values for predictive models.

Another important observation from our study is that u11-d-TXB₂ levels, in particular, were affected by the proximity of the urine sampling to a colonoscopy. A plausible hypothesis is that either bowel preparation, the colonoscopy itself, or both, lead to increased prostanoïd synthesis based on the data on increased plasma TXB₂ levels during and immediately after colonoscopy from Berger et al.²³ Our observation that plasma 15-hydroxyeicosatetraenoic (HETE) acid (a C20:4n-6 arachidonic acid metabolite) levels are increased in blood samples, which were taken at the same time as the urine sample at V6, compared to V4 samples, is also compatible with provocation of COX-dependent prostanoïd synthesis during colonoscopy.³¹

Importantly, although urine samples were stored for several years at -80°C in the seAFOod trial biobank before analysis, both urinary metabolites are considered stable over a wide temperature range and for long periods of time.^{32,33} Therefore, we do not consider degradation of analytes to have contributed to these findings.

Limitations of this secondary biomarker analysis of the seAFOod trial include incomplete coverage of the original trial cohort, leading to small group sizes for some treatment group analyses. In turn, there are wide confidence intervals around some point estimates for the relationships between urinary biomarker values and colorectal polyp outcomes in the individual trial treatment groups that should be interpreted with caution.

We were, however, able to leverage trial data on treatment compliance to complete sensitivity analysis of a per-protocol population and explore the contribution of treatment cessation to changes of the urinary biomarker data.

In summary, we report the effects of aspirin and EPA on urinary biomarkers of COX-1 and COX-2 activity in individuals with a history

of multiple colorectal polyps taking part in the seAFOod polyp prevention trial. Urinary PGE-M levels are highly variable over time and do not appear to have utility for colorectal polyp risk or therapeutic response prediction for aspirin or EPA. However, we suggest that u11-d-TXB₂ should be further investigated as a potential biomarker of colorectal polyp risk, with which to guide a precision approach to aspirin use for cancer chemoprevention.

AUTHOR CONTRIBUTIONS

The work reported in the paper has been performed by the authors, unless clearly specified in the text. Paul M. Loadman and Mark A. Hull conceived and designed the study. Mark A. Hull and Amy Downing gained approvals for the study. Ge Sun, Harriett Fuller, Hayley Fenton, Amanda D. Race, Amy Downing, Paul M. Loadman and Mark A. Hull were involved in the acquisition, analysis, or interpretation of data. Drafting of the manuscript was done by Ge Sun, Harriett Fuller, Amy Downing and Mark A. Hull. Elizabeth A. Williams, Colin J. Rees, Louise C. Brown, Paul M. Loadman and Mark A. Hull obtained funding for the study. All the authors contributed to the critical review and final approval of the manuscript. Ge Sun, Harriett Fuller, Amy Downing and Mark A. Hull have accessed and verified the underlying data. All authors were responsible for the decision to submit the manuscript.

ACKNOWLEDGEMENTS

The authors wish to thank all the participants and research staff who contributed to the seAFOod polyp prevention trial. The authors also acknowledge the significant contribution of Mr John Whelpton acting as the Patient & Public representative in the STOP-ADENOMA Study Group.

FUNDING INFORMATION

This project (NIHR128210) was funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The views expressed in this publication are those of the authors and not necessarily those of the MRC, NIHR or the Department of Health and Social Care. MAH and CJR are NIHR Senior Investigators. Amy Downing and Mark A. Hull are supported by Cancer Research UK grant C23434/A24939.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of our study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

Our study is part of a wider programme of investigations using the seAFOod trial biobank and posttrial BCSP colonoscopy outcomes called STOP-ADENOMA (ISRCTN05926847). Ethical approval for our study was granted by London and Surrey Borders Research Ethics Committee (19/LO/1655). All participants of the seAFOod trial provided written informed consent to collect data on posttrial BCSP outcomes and to use urine and blood samples for laboratory studies.

ORCID

Mark A. Hull  <https://orcid.org/0000-0001-7414-1576>

TWITTER

Mark A. Hull  [mark_tbh](#)

REFERENCES

- Hull MA, Sprange K, Hepburn T, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. *Lancet*. 2018;392:2583-2594.
- Hull MA, Sprange K, Hepburn T, et al. Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. *Efficacy Mech Eval*. 2019;6:4-154.
- Drew DA, Chan AT. Aspirin in the prevention of colorectal neoplasia. *Ann Rev Med*. 2021;72:415-430.
- Downing A, Fenton H, Nickerson C, et al. Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: evidence of 'rebound' elevated colorectal polyp risk after short-term aspirin use. *Aliment Pharmacol Therap*. 2023;58:562-572. doi:10.1111/apt17646
- Ballerini P, Contursi A, Bruno A, Mucci M, Tacconelli S, Patrignani P. Inflammation and cancer: from the development of personalized indicators to novel therapeutic strategies. *Front Pharmacol*. 2022;13:838079.
- Smith WL. Cyclooxygenases, peroxide tone and the allure of fish oil. *Curr Opin Cell Biol*. 2005;17:174-182.
- Drew DA, Schuck MM, Magicheva-Gupta MV, et al. Effect of low-dose and standard-dose aspirin on PGE₂ biosynthesis among individuals with colorectal adenomas: a randomized clinical trial. *Cancer Prev Res*. 2020;13:877-888.
- White MN, Shrubsole MJ, Cai Q, et al. Effects of fish oil supplementation on eicosanoid production in subjects at higher risk for colorectal cancer. *Eur J Cancer Prev*. 2019;28:188-195.
- Fedirko V, Bradshaw PT, Figueiredo JC, et al. Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the aspirin/folate polyp prevention study (AFPPS). *Cancer Prev Res*. 2015;8:1061-1068.
- Bezawada N, Song M, Wu K, et al. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. *Cancer Prev Res*. 2014;7:758-765.
- Simeone P, Boccatonda A, Liani R, Santilli F. Significance of urinary 11-dehydro-thromboxane B₂ in age-related diseases: focus on atherothrombosis. *Ageing Res Rev*. 2018;48:51-78.
- Lopez LR, Guyer KE, Torre IG, Pitts KR, Matsuura E, Ames PR. Platelet thromboxane (11-dehydro-thromboxane B₂) and aspirin response in patients with diabetes and coronary artery disease. *World J Diabetes*. 2014;5:115-127.
- Yamada M, Omata K, Abe F, Ito S, Abe K. Changes in prostacyclin, thromboxane A₂ and F₂-isoprostanes and influence of eicosapentaenoic acid and anti-platelet agents in patients with hypertension and hyperlipidemia. *Immunopharmacology*. 1999;44:193-198.
- Sciulli MG, Filabozzi P, Tacconelli S, et al. Platelet activation in patients with colorectal cancer. *Prostaglandins Leukot Essent Fatty Acids*. 2005;72:79-83.
- Rutter MD, East J, Rees CJ, et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. *Gut*. 2020;69:201-223.
- Hull MA, Sandell AC, Montgomery AA, et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening programme (The seAFOod Polyp Prevention trial): study protocol for a randomized controlled trial. *Trials*. 2013;14:237.
- Bonithon-Kopp C, Piard F, Fenger C, et al. Colorectal adenoma characteristics as predictors of recurrence. *Dis Colon Rectum*. 2004;47:323-333.
- Chi Z, Lin Y, Huang J, et al. Risk factors for recurrence of colorectal conventional adenoma and serrated polyp. *Gastroenterol Rep*. 2021;10:goab038. doi:10.1093/gastro/goab038
- Johnson JC, Schmidt CR, Shrubsole MJ, et al. Urine PGE-M: a metabolite of prostaglandin E₂ as a potential biomarker of advanced colorectal neoplasia. *Clin Gastroenterol Hepatol*. 2006;4:1358-1365.
- Duffield-Lillico AJ, Boyle JO, Zhou XK, et al. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. *Cancer Prev Res*. 2009;2:322-329.
- Lowe FJ, Gregg EO, McEwan M. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. *Clin Chem Lab Med*. 2009;47:311-320.
- Calapai G, Caputi AP, Mannucci C, et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. *Basic Clin Pharmacol Toxicol*. 2009;104:322-328.
- Berger D, Boelke E, Stanescu A, et al. Endotoxaemia and mediator release during colonoscopy. *Endoscopy*. 1995;27:671-675.
- Patrono C. Cyclooxygenase inhibitors and cancer: the missing pieces. *J Pharmacol Exp Therap*. 2023;386:181-189. doi:10.1124/jpet.122.001631
- Nowak J, Murray JJ, Oates JA, Fitzgerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. *Circulation*. 1987;76:6-14.
- Rade JJ, Barton BA, Vasan RS, et al. Association of thromboxane generation with survival in aspirin users and nonusers. *J Am Coll Cardiol*. 2022;80:233-250.
- Patrono C, Rocca B. Measurement of thromboxane biosynthesis in health and disease. *Front Pharmacol*. 2019;10:1244.
- Joharatnam-Hogan N, Hatem D, Cafferty FH, et al. Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial. *Br J Cancer*. 2023;129:706-720. doi:10.1038/s41416-023-02310-1
- Lanas A, Tacconelli S, Contursi A, et al. Biomarkers of response to low-dose aspirin in familial adenomatous polyposis patients. *Cancer*. 2023;15:2457.
- Bachmair EM, Ostertag LM, Zhang X, de Roos B. Dietary manipulation of platelet function. *Pharmacol Therap*. 2014;144:97-113.
- Fuller H, Race AD, Fenton H, et al. Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial. *Prostaglandins Leukot Ess Fatty Acids*. 2023;19:102570.
- Sterz K, Scherer G, Ecker J. A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids. *J Lipid Res*. 2012;53:1026-1036.
- Pagliaccia F, Habib A, Pitocco D, et al. Stability of urinary thromboxane A₂ metabolites and adaptation of the extraction method to small urine volume. *Clin Lab*. 2014;60:105-111.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Sun G, Fuller H, Fenton H, et al. The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E₂ synthesis and platelet activation in participants of the seAFOod polyp prevention trial. *Int J Cancer*. 2023;1-13. doi:10.1002/ijc.34764

B-cell malignancies - A new knowledge hub on the latest research in therapeutic advances

**EDUCATIONAL CONTENT AVAILABLE ON
THE HUB:**

- **On-demand Webinars - earn CME credit**
 - **Infographics**
 - **Patient Case Studies**
 - **Curated Research Articles**
- ...and much more**

VISIT KNOWLEDGE HUB TODAY

This educational resource has been supported by Eli Lilly.

WILEY